Authors: Khan, OA Zvartau-Hind, M Caon, C Din, MU Cochran, M Lisak, D Tselis, AC Kamholz, JA Garbern, JY Lisak, RP

Citation: Oa. Khan et al., Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy, MULT SCLER, 7(3), 2001, pp. 185-188

Authors: Khan, OA Tselis, AC Kamholz, JA Garbern, JY Lewis, RA Lisak, RP

Citation: Oa. Khan et al., Appropriate design and outcome measures in multiple sclerosis clinical trials - Response, EUR J NEUR, 8(5), 2001, pp. 505-506

Authors: Khan, OA Tselis, AC Kamholz, JA Garbern, JY Lewis, RA Lisak, RP

Citation: Oa. Khan et al., A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis, EUR J NEUR, 8(2), 2001, pp. 141-148

Authors: Ebright, JR Stellini, MA Tselis, AC

Citation: Jr. Ebright et al., Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy, CLIN INF D, 32(5), 2001, pp. E90-E91

Authors: Clifford, DB Yiannoutsos, C Glicksman, M Simpson, DM Singer, EJ Piliero, PJ Marra, CM Francis, GS McArthur, JC Tyler, KL Tselis, AC Hyslop, NE

Citation: Db. Clifford et al., HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy, NEUROLOGY, 52(3), 1999, pp. 623-625

Authors: Tselis, AC Lisak, RP

Citation: Ac. Tselis et Rp. Lisak, Multiple sclerosis - Therapeutic update, ARCH NEUROL, 56(3), 1999, pp. 277-280